46 results about "Propiolactone" patented technology

An element of an absorbent article is provided. The element has a bio-based content of at least about 50% based on the total weight of the element, and comprises a synthetic polymer derived from a renewable resource via a first intermediate compound selected from the group consisting of crotonic acid, propiolactone, ethylene oxide, i-propanol, butanol, butyric acid, propionic acid, 2-acetoxypropanoic acid, methyl 2-acetoxypropanoate, methyl lactate, ethyl lactate, polyhydroxybutyrate, and a polyhydroxyalkanoate comprising 3-hydroxypropionate monomers. An absorbent article comprising the element and a method of making an element for an absorbent article also are provided.

The integrated processes herein provide improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Provided are also ethylene oxide carbonylation products such as beta-propiolactone and succinic anhydride having a bio-based content between 0% and 100%, and methods for producing and analyzing the same.

The invention relates to a nanomicelle of magnetic tumor double-targeting polymer and a preparation method thereof. The nanomicelle of magnetic tumor double-targeting polymer is a nuclear shell structure; the surface of an outer shell is connected with targeted ligand, an inner core is enclosed with nano-particles of super paramagnetic ferriferrous oxide and anticarcinogen with hydrophobic property; in virtue of the physical effect of an external magnetic field and induction of the targeting ligand, the tumor double-targeting function of the nanomicelle is realized. The invention also provides the preparation method of the nanomicelle of magnetic tumor double-targeting polymer: polyethylene glycol with end capping by folacin, and poly Epsilon-caprolactone or sandwich copolymer of poly propiolactone are taken as raw materials and enclosed with the nano-particles of super paramagnetic ferriferrous oxide and the anticarcinogen with hydrophobic property, and then dialysed to obtain the nanomicelle of magnetic tumor double-targeting polymer. The drug carrier system of the nanomicelle reinforces the treatment effect of the anticarcinogen with hydrophobic property on tumor, prolongs the circulating time of the anticarcinogen in human body, intensifies the targeting action of drugs, improves the release efficiency and partial concentration of drugs, and reduces the dosage and toxic and side effect of drugs.

The invention discloses a method for preparing a purified foot-and-mouth disease vaccine, a serum or animal-derived ingredient free culture medium and an application of the serum or animal-derived ingredient free culture medium to the preparation of the foot-and-mouth disease vaccine, belonging to the filed of biotechnology. The method for preparing the purified foot-and-mouth disease vaccine comprises the following steps of: culturing a foot-and-mouth disease virus by using the serum or animal-derived ingredient free culture medium, purifying an obtained virus solution to obtain a purified antigen, subjecting a cell strain BHK-21 or BSR to the multiple-generation acclimatization culture and the suspension culture by 300L of a microcarrier through the serum-free culture medium, inoculating the cell strain BHK-21 or BSR against the foot-and-mouth disease vaccine, stirring at the rotating speed of 30-50rpm, microfiltrating, ultrafiltrating, concentrating 50-200 times, carrying out chromatography with a Sephawse6FF molecular sieve or density gradient zonal centrifugation with a continuous flow, and inactivating with beta-propiolactone to obtain the serotype univalent or multivalent vaccine for cattle, sheep and pigs.

The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.

The invention discloses a preparation method of a swine vaccine specific swine spleen transfer factor (TF). The preparation method comprises the following steps: slaughtering a swine with a positive swine vaccine antibody to harvest the swine spleen; preserving the swine spleen at low temperature; unfreezing the swine spleen; removing fasciae; mincing the swine spleen; homogenizing the pulp; filling the homogenized pulp into a bottle and storing the pulp; repeatedly freezing and thawing the pulp; centrifuging the pulp; carrying out microfiltration; carrying out ultrafiltration; carrying out inactivation; regulating the pH value; regulating the osmotic pressure; removing bacteria; and detecting the quality. The preparation method has the advantages that the pH value of water for injection is regulated to 4-6 in the pulp homogenizing step, thus being beneficial to increasing of the yields of ribose and polypeptide; a box type membrane coating is adopted for tangential flow filtration, so that the dead volumes of system residues are small and linear amplification production is easy to achieve; a 1-3KD box type membrane coating is adopted to carry out tangential flow nanofiltration on a TF crude product, thus preparing the high-concentration TF and improving the using effects; phenol red is used as an acid-base indicator, thus being convenient for clients to observe the pH value of the TF; the TF uses beta-propiolactone for inactivation instead of traditional formaldehyde and an osmotic pressure regulation process is added, thus being beneficial to combined immunization of the TF and vaccines.

The present invention provides for pharmaceutical compositions comprising pancreatic enzyme preparations (PEPs) with viral infectivity reduced below significant levels and having high enzymatic activity. The PEPs can comprise lipases, proteases, amylases, non-enveloped viruses (e.g., porcine parvovirus (PPV), porcine circovirus type 2 (PCV-2), porcine encephalomyocarditis virus (EMCV)), and enveloped viruses (e.g., vesicular stomatitis virus (VSV), and influenza A (IFA)). The present invention also includes methods of treating pancreatic insufficiency by administering these pharmaceutical compositions and methods of making the same by treating the PEP with beta-propiolactone (BPL) to reduce viral infectivity.

The invention provides a preparation method of carboxylic acid betaine modified non-woven fabric for hemofiltration, belonging to the field of biological medical material. The method comprises the following steps of: under the action of photosensitizer and ultraviolet light, grafting N, N dimethyl acrylamide (DMAA) with tert-amido, and then introducing propiolactone to react with the tert-amido to generate a carboxylic acid betaine group. The preparation method is simple in preparation process, easy to realize, explicit and reliable in mechanism; and the carboxylic acid betaine modified non-woven fabric is good in hydrophily and blood compatibility and can be applied to blood filter material and the other biological medical fields.

Provided herein are systems, and methods of using such systems, for producing superabsorbent polymers from ethylene oxide and carbon monoxide. The production systems have various unit operations, including, for example, a beta-propiolactone production system configured to produce beta-propiolactone from ethylene oxide and carbon monoxide and a superabsorbent polymer production system configured toproduce superabsorbent polymers from beta-propiolactone and / or acrylic acid.

The invention discloses a preparation method of a swine vaccine specific cattle spleen transfer factor (TF). The preparation method comprises the following steps: slaughtering a cattle with a positive swine vaccine antibody to harvest the cattle spleen; preserving the cattle spleen at low temperature; unfreezing the cattle spleen; removing fasciae; mincing the cattle spleen; homogenizing the pulp; filling the homogenized pulp into a bottle and storing the pulp; repeatedly freezing and thawing the pulp; centrifuging the pulp; carrying out microfiltration; carrying out ultrafiltration; carrying out inactivation; regulating the pH value; regulating the osmotic pressure; removing bacteria; and detecting the quality. The preparation method has the advantages that the pH value of water for injection is regulated to 4-6 in the pulp homogenizing step, thus being beneficial to increasing of the yields of ribose and polypeptide; a box type membrane coating is adopted for tangential flow filtration, so that the dead volumes of system residues are small and linear amplification production is easy to achieve; a 1-3KD box type membrane coating is adopted to carry out tangential flow nanofiltration on a TF crude product, thus preparing the high-concentration TF and improving the using effects; phenol red is used as an acid-base indicator, thus being convenient for clients to observe the pH value of the TF; the TF uses beta-propiolactone for inactivation instead of traditional formaldehyde and an osmotic pressure regulation process is added, thus being beneficial to combined immunization of the TF and vaccines.

The granular pesticide preparation for preventing and controlling smaller brown planthopper in wheat field consists of chlorpyrifos, DDVP, stabilizer A, stabilizer B, colorizing agent and carrier in certain weight proportion. The stabilizer A is butyrolactone, gamma-propiolactone or delta-propiolactone; the stabilizer B is 1, 2-butanediol, 2-methyl-2, 4-pentanediol or [1, 5]-pentanediol; the colorizing agent is red powder, phthalocyanine red or acid scarlet; and the carrier is coal slack, perlite or vermiculite. The granular pesticide preparation as re-compounded pesticide has synergistic effect of killing smaller brown planthopper and other effect.

The invention belongs to the field of coffee essence preparation methods, and relates to a coffee essence preparation method. The method comprises the following steps: S10, raw material weighing; S20, material feeding and production; and S30, packaging, wherein in the step S10, the weighed raw materials and proportions are as follows in weight percentage: 0.07-0.09% of beta-propiolactone, 0.07-0.09% of green cognac oil, 0.09-0.11% of benzoic acid, 0.25-0.29% of n-hexanoic acid, 0.36-0.4% of ethyl acetate, 0.36-0.4% of methyl maltol, 0.29-0.35% of butanedione, 0.6-0.8% of furfuryl mercaptan, 9-11% of red date extract, 8-10% of vanillin, 18-20% of coffee extract, 8-10% of ethyl alcohol, and the balance of distilled water. Through the ingredients and proportions, the rich taste of coffee can be increased while the coke fragrance of coffee is guaranteed; in addition, solids can be dissolved first for preventing the volatilization of ingredients with small proportions.

The invention provides a nucleic acid extraction-free inactivated virus preserving fluid and application thereof, and particularly, the virus sample preserving fluid comprises protease K, sodium hydroxide, beta-propiolactone, gelatin and other components, and virus nucleic acid can be effectively released and preserved at room temperature through the synergistic cooperation of the components. Nucleic acid degradation is effectively prevented in the normal-temperature transportation and storage process of the sample, and the method can be used for preparing clinical viral nucleic acid samples.

The invention provides a preparation method of a poultry vaccine dilution liquid, and belongs to the technical field of biomedicine. The preparation method comprises: mixing chicken bursa, chicken intestine and water, homogenizing, carrying out repeated freezing-thawing on the obtained homogenized liquid, mixing the obtained freezing-thawing liquid and acetic acid, sequentially carrying out stirring and centrifugation, mixing the obtained centrifugation supernatant and beta-propiolactone, inactivating, hydrolyzing the obtained inactivated liquid for 1-3 h at a temperature of 35-42 DEG C, carrying out micro-filtration on the obtained hydrolyzate, adjusting the pH value of the obtained micro-filtrate, carrying out ultra-filtration on the obtained adjusted liquid, and sterilizing the obtainedultra-filtrate to obtain the poultry vaccine dilution liquid. According to the present invention, the poultry vaccine dilution liquid prepared through the preparation method can completely kill the non-specific pathogenic bacteria of poultry vaccine, and can ensure the safe use of the vaccine.

The invention belongs to the technical field of biodegradable medical polymer materials, and particularly relates to a main chain type biodegradable liquid crystal polymer and a preparation method thereof. Natural products such as cholesterin, diosgenin, menthol, isosorbide and the like are used as liquid crystal nucleuses; a hydroxyl-terminated alkanoic acid or an amino-terminated acid is used asa flexible spacer to prepare a liquid crystal intermediate; ring opening polymerization reaction on one or a mixture of two or more than two of following monomers or derivatives from trimethylene carbonate, caprolactone, lactide, glycolide, p-dioxanone, propiolactone, butyrolactone, octolactone, caprolactam, morpholine-2, 3-diketone, and a dianhydride are initiated by taking the liquid crystal intermediate as an initiator, so as to obtain the main chain type biodegradable liquid crystal polymer. The main chain type biodegradable liquid crystal polymer provided by the invention has good liquidcrystal performance, is easy to orientate to form an ordered structure, not only generates response to the outside factors of temperature, pH, stress, electric field, magnetic field and the like, butalso has good biocompatibility and degradation performance.

The invention provides rooting liquid for a jujube tree scion. The rooting liquid comprises, by weight, 11-16 parts of 2-naphthalene acetic acid, 8-12 parts of geniposide, 5-8 parts of sodium 4-chlorophenoxyacetate, 3-6 parts of beta-propiolactone, 4-8 parts of baicalin, 6-10 parts of zeatin riboside, 15-20 parts of sucrose, 5-9 parts of vitamin B5, 3-7 parts of dimethyl sulfoxide, 160-200 parts of ethanol and 1000-1200 parts of water. The rooting liquid can increase the rooting rate of the jujube tree scion and shorten a rooting cycle.

The invention relates to a plasmid anticoagulant having a virus inactivation function. With 4% sodium citrate which is collected in a blood test as a basic anticoagulant, the virus inactivation function of the plasmid anticoagulant is achieved by adding one or more virus inactivating agents selected from sodium caprylate, formaldehyde and [beta]-propiolactone. With the application of the plasma anticoagulant having a recheck function provided by the invention, the risk of personnel infection due to exposure of positive plasma in a storing, transporting or using process after the collection of the plasma can be effectively prevented, so that the bio-safety of the plasma in an entire life cycle from the collection of the plasma can be guaranteed.

The invention discloses a cationic polymer gene vector and a preparation method thereof, the cationic polymer gene vector is modified polyglycidyl amine, and a modification agent is p-methylbenzenesulfonyl terminated polyethylene glycol monomethyl ether, carboxyl terminated polyethylene glycol monomethyl ether, oligosaccharide, an organic hydrophobic substance or zwitter-ions. The oligosaccharide is at least one of maltose, glucose and mannose, the organic hydrophobic substance is at least one of lauric acid, lauric aldehyde, polylactic acid, polycaprolactone, a lactic-co-glycolic acid copolymer and cholesterol, and the zwitterions are at least one of propiolactone, butyrolactone, valerolactone, caprolactone, 1, 3-propane sultone, 1, 4-butane sultone, and 1, 5-pentane sultone; wherein the grafting rate of the modification agent on the polyglycidyl amine is 5%-50%. The modified polyglycidyl amine provided by the invention is used as a non-viral gene transfection vector, and has very high biocompatibility and gene transfection capability and relatively low cytotoxicity.

The invention relates to a preparation method of beta-propiolactone, the preparation method comprises the following steps: (1) dissolving 3-halogenated propionic acid in an organic solvent at a room temperature, stirring, cooling to a temperature of 0 DEG C or less, and adding organic amine to obtain a solution A; preparing alkali liquor below 0 DEG C as a solution B; (2) mixing the solution A and the solution B under stirring at 0-2 DEG C, then heating to 4-6 DEG C, carrying out a heat preservation reaction, stopping stirring after the reaction is completed, cooling to 0 DEG C, and standing to generate split phases; and (3) washing the organic phase obtained by phase splitting with salt water, cooling to 0 DEG C or below, washing with water, drying, desolventizing to obtain a crude product beta-propiolactone, and distilling to obtain the product beta-propiolactone. According to the method, the reaction technology combining extraction and phase transfer is adopted, the reaction is carried out at low temperature, beta-propiolactone can be prepared at high yield, the used raw materials are easy to obtain, the cost is low, the preparation process is simple, and the method is suitable for industrial production.

An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using β-propiolactone, a non-ionic detergent, particularly n-octyl-α-D-glucopyranoside and n-octyl-β-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.

The invention relates to a method for removing chick embryo host protein in a rabies vaccine product. The method comprises the following steps of: filtering and concentrating harvested virus chick embryo cell culture supernatant, performing washing and filtering by using a phosphate buffer solution containing sodium chloride and arginine, and adding beta-propiolactone for inactivating and hydrolyzing; and adding human serum albumin, performing standing at low temperature, and performing ultrasonic treatment and purification to obtain the rabies vaccine product purified liquid without the chick embryo host protein. According to the method, the human serum albumin is added, so that the influence of ultrasonic waves on virus particles can be effectively reduced, and the content of impure protein in the product is further reduced. The inactivated hydrolysate is subjected to ultrasonic treatment through an ultrasonic cleaning machine, the cleanliness requirement is low, the operation difficulty is low, and the stability is high.

A thermoplastic elastomer for profile control and water shutoff is prepared from the following raw materials in parts by weight: 8-10 parts of a component A, 1-3 parts of a strong acid, 1-3 parts of a hydrophobic modifier and 100-105 parts of water. The component A is one of polyethylene glycol, polyvinylether, polyvinyl alcohol, copolymer of acrylamide and acrylonitrile. The strong acid is one of concentrated hydrochloric acid and concentrated sulfuric acid. The hydrophobic modifier is any one of formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, β-propiolactone, γ-butyrolactone, δ-valerolactone, methyltriacetylsilane, methyltrimethylsilane, butyl acrylate and ethylene glycol dimethacrylate. The thermoplastic elastomer for profile control and water shutoff provided by the disclosure has the advantages of one-step preparation and molding, strong deformation capability, temperature resistance, salt tolerance, strong stability and the like, and is suitable for large-scale production and application.

The present invention discloses bovine parainfluenza virus PBIV3-B strain and application thereof, the bovine parainfluenza virus PBIV3-B strain has the advantages of good immunogenicity and culture characteristics and the like, the bovine parainfluenza virus PBIV3-B strain is inoculated into MDBK cell to obtain a culture matter, after the culture matter is inactivated with (beta-Propiolactone), the culture matter is mixed with commercial MontanideTMISA15AVG adjuvant of SEPPIC of France for emulsion to obtain a bovine parainfluenza virus inactivated vaccine. Results showed that when the bovine parainfluenza virus inactivated vaccine prepared by the method is used for immunization of a weaned healthy negative cow, diseases caused by the bovine parainfluenza virus type 3 can be prevented, and the bovine parainfluenza virus inactivated vaccine has the advantages of safety, fast antibody production and lasting immunity period and the like.